The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Antidepressant-Induced Liver Injury: A Review for Clinicians
Abstract
OBJECTIVE: Antidepressant drugs can cause drug-induced liver injury (DILI). The authors review clinical data relevant to antidepressant-induced liver injury and provide recommendations for clinical practice. METHOD: A PubMed search was conducted for publications from 1965 onward related to antidepressant-induced liver injury. The search terms were "liver injury," "liver failure," "DILI," "hepatitis," "hepatotoxicity," "cholestasis," and "aminotransferase," cross-referenced with "antidepressant." RESULTS: Although data on antidepressant-induced liver injury are scarce, 0.5%-3% of patients treated with antidepressants may develop asymptomatic mild elevation of serum aminotransferase levels. All antidepressants can induce hepatotoxicity, especially in elderly patients and those with polypharmacy. Liver damage is in most cases idiosyncratic and unpredictable, and it is generally unrelated to drug dosage. The interval between treatment initiation and onset of liver injury is generally between several days and 6 months. Life-threatening antidepressant-induced liver injury has been described involving fulminant liver failure or death. The underlying lesions are often of the hepatocellular type and less frequently of the cholestatic and mixed types. The antidepressants associated with greater risks of hepatotoxicity are iproniazid, nefazodone, phenelzine, imipramine, amitriptyline, duloxetine, bupropion, trazodone, tianeptine, and agomelatine. The antidepressants that seem to have the least potential for hepatotoxicity are citalopram, escitalopram, paroxetine, and fluvoxamine. Cross-toxicity has been described, mainly for tricyclic and tetracyclic antidepressants. CONCLUSIONS: Although an infrequent event, DILI from antidepressant drugs may be irreversible, and clinicians should be aware of it. Aminotransferase surveillance is the most useful tool for detecting DILI, and prompt discontinuation of the drug responsible is essential. The results of antidepressant liver toxicity in all phases of clinical trials should be available and published. Further research is needed before any new and rigorously founded recommendations can be made.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Timing of new black box warnings and withdrawals for prescription medications
Lasser, K. E. (2002) · JAMA · doi:10.1001/jama.287.17.2215 · Cited by 1,005
Case definition and phenotype standardization in drug-induced liver injury
Aithal, G. P., Watkins, P. B., Andrade, R. J., Larrey, D., Molokhia, M., Takikawa, H., Hunt, C. M., Wilke, R. A., Avigan, M., Kaplowitz, N., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.58 · Cited by 944
ANDRADE, R., LUCENA, M., FERNANDEZ, M., PELAEZ, G., PACHKORIA, K., GARCIARUIZ, E., GARCIAMUNOZ, B., GONZALEZGRANDE, R., PIZARRO, A., & DURAN, J. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.006 · Cited by 856
Incidence of drug-induced hepatic injuries: A French population-based study
Sgro, C., Clinard, F., Ouazir, K., Chanay, H., Allard, C., Guilleminet, C., Lenoir, C., Lemoine, A., & Hillon, P. (2002) · Hepatology · doi:10.1053/jhep.2002.34857 · Cited by 716
Outcome and prognostic markers in severe drug‐induced liver disease†
Björnsson, E., & Olsson, R. (2005) · Hepatology · doi:10.1002/hep.20800 · Cited by 524
Why Drugs Fail - A Study on Side Effects in New Chemical Entities
Schuster, D., Laggner, C., & Langer, T. (2005) · Current Pharmaceutical Design · doi:10.2174/138161205774414510 · Cited by 417
Nemeroff, C. B., Evans, D. L., Gyulai, L., Sachs, G. S., Bowden, C. L., Gergel, I. P., Oakes, R., & Pitts, C. D. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.906 · Cited by 407
Lammert, C., Einarsson, S., Saha, C., Niklasson, A., Bjornsson, E., & Chalasani, N. (2008) · Hepatology · doi:10.1002/hep.22272 · Cited by 389
Chen, M., Borlak, J., & Tong, W. (2013) · Hepatology · doi:10.1002/hep.26208 · Cited by 348
Acute Hepatitis E Infection Accounts for Some Cases of Suspected Drug-Induced Liver Injury
Davern, T. J., Chalasani, N., Fontana, R. J., Hayashi, P. H., Protiva, P., Kleiner, D. E., Engle, R. E., Nguyen, H., Emerson, S. U., Purcell, R. H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.051 · Cited by 328
Tollefson, G. D. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950070051010 · Cited by 314
CLINICAL PHARMACOLOGY OF IMIPRAMINE AND RELATED ANTIDEPRESSANT COMPOUNDS
KLERMAN, G. L., & Cole, J. O. (1965) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)07033-4 · Cited by 303
Lucena, M. I., Andrade, R. J., Kaplowitz, N., García‐Cortes, M., Fernández, M. C., Romero‐Gomez, M., Bruguera, M., Hallal, H., Robles‐Diaz, M., Rodriguez‐González, J. F., et al. (2009) · Hepatology · doi:10.1002/hep.22895 · Cited by 290
Clinical pharmacology of imipramine and related antidepressant compounds.
KLERMAN, G. L., & Cole, J. O. (1967) · PubMed · Cited by 272
Fromenty, B., & Pessayre, D. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80496-5 · Cited by 267
Gartlehner, G., Gaynes, B. N., Hansen, R. A., Thieda, P., DeVeaugh-Geiss, A., Krebs, E. E., Moore, C. G., Morgan, L., & Lohr, K. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-00008 · Cited by 237
Kasper, S., & Olié, J. P. (2002) · European Psychiatry · doi:10.1016/s0924-9338(02)00651-x · Cited by 232
The Safety of Fluoxetine - An Update
Cooper, G. L. (1988) · British Journal of Psychiatry · doi:10.1192/s000712500029733x · Cited by 228
Isoniazid and Iproniazid: Activation of Metabolites to Toxic Intermediates in Man and Rat
Nelson, S. D., Mitchell, J. R., Timbrell, J. A., Snodgrass, W. R., & Corcoran, G. B. (1976) · Science · doi:10.1126/science.7838 · Cited by 226
Andersson, T., Miners, J., Veronese, M., & Birkett, D. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04336.x · Cited by 225
Safety of mirtazapine: a review
Montgomery, S. A. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199512004-00006 · Cited by 214
Diagnosis, management and prevention of drug-induced liver injury
Verma, S., & Kaplowitz, N. (2009) · Gut · doi:10.1136/gut.2008.163675 · Cited by 192
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.7.876 · Cited by 190
Metabolic Syndrome Predisposes to Depressive Symptoms: A Population-Based 7-Year Follow-Up Study
Koponen, H., Jokelainen, J., Keinänen-Kiukaanniemi, S., Kumpusalo, E., & Vanhala, M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0202 · Cited by 177
Safety of Newly Approved Drugs: Implications for Prescribing
Temple, R. J., & Himmel, M. H. (2002) · JAMA · doi:10.1001/jama.287.17.2273 · Cited by 173
Donepezil in Alzheimer’s disease: from conventional trials to pharmacogenetics
Cacabelos, R. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a908 · Cited by 164
Long‐term evaluation of paroxetine, clomipramine and placebo in panic disorder
Lecrubier, Y., Judge, R., & The Collaborative Paroxetine Panic Study Investigators (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb00389.x · Cited by 139
Sundaram, V., & Björnsson, E. S. (2017) · Hepatology Communications · doi:10.1002/hep4.1088 · Cited by 138
Greist, J. H., Jefferson, J. W., Kobak, K. A., Chouinard, G., DuBoff, E., Halaris, A., Kim, S. W., Koran, L. M., Liebowtiz, M. R., Lydiard, B., et al. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199506000-00001 · Cited by 133
The Safety and Tolerability of Venlafaxine Hydrochloride: Analysis of the Clinical Trials Database
Rudolph, R. L., & Derivan, A. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199606002-00011 · Cited by 127
Hepatotoxicity of Psychotropic Drugs
Selim, K., & Kaplowitz, N. (1999) · Hepatology · doi:10.1002/hep.510290535 · Cited by 119
Hepatotoxicity Associated With the New Antidepressants
García‐Pando, A. C., del Pozo, J. G., Sanchez, A., Martín, A. V., de Castro, A. M. R., & Lucena, M. I. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0208 · Cited by 109
Relevant Issues in the Monitoring and the Toxicology of Antidepressants
Wille, S. M. R., Cooreman, S., Neels, H. M., & Lambert, W. E. (2008) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360701713112 · Cited by 109
The safety profile of paroxetine.
Wf, B., & Blumhardt, C. L. (1992) · PubMed · Cited by 103
Nefazodone-Induced Liver Failure: Report of Three Cases
Aranda‐Michel, J., Koehler, A., Bejarano, P. A., Poulos, J., Luxon, B. A., Khan, C. M., Ee, L. C., Balistreri, W. F., & Weber, F. L. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-4-199902160-00013 · Cited by 102
An Open-Label Trial of Citalopram for Major Depression in Patients With Hepatitis C
Gleason, O. C., Yates, W. R., Isbell, M. D., & Philipsen, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0304 · Cited by 100
Antidepressant-lnduced Liver Injury
DeSanty, K. P., & Amabile, C. M. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k114 · Cited by 98
Interaction of methadone with substrates of human hepatic cytochrome P450 3A4
Iribarne, C., Dréano, Y., Bardou, L., Menez, J. F., & Berthou, F. (1997) · Toxicology · doi:10.1016/s0300-483x(96)03549-4 · Cited by 91
Purkins, L., Love, E. R., Eve, M. D., Wooldridge, C. L., Cowan, C., Smart, T. S., Johnson, P. J., & Rapeport, G. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01969.x · Cited by 89
Bjornsson, E. S., & Jonasson, J. G. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.11.002 · Cited by 89
Tsoi, D. T.-Y., Porwal, M., & Webster, A. C. (2010) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.109.066019 · Cited by 83
Hepatic Adverse Reactions Associated with Nefazodone
Stewart, D. E. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700409 · Cited by 80
Duloxetine hepatotoxicity: a case‐series from the drug‐induced liver injury network
Vuppalanchi, R., Hayashi, P. H., Chalasani, N., Fontana, R. J., Bonkovsky, H. L., Saxena, R., Kleiner, D. E., Hoofnagle, J. H., & the Drug‐Induced Liver Injury Network (DILIN) (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04449.x · Cited by 78
Transaminase elevation on placebo during Phase I trials: prevalence and significance
Rosenzweig, Miget, & Brohier (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00952.x · Cited by 78
Gelenberg, A. J., Trivedi, M. H., Rush, A. J., Thase, M. E., Howland, R., Klein, D. N., Kornstein, S. G., Dunner, D. L., Markowitz, J. C., Hirschfeld, R. M. A., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01971-6 · Cited by 76
Leombruni, P., Pierò, A., Lavagnino, L., Brustolin, A., Campisi, S., & Fassino, S. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.06.005 · Cited by 76
Schaefer, M., Sarkar, R., Knop, V., Effenberger, S., Friebe, A., Heinze, L., Spengler, U., Schlaepfer, T. E., Reimer, J., Buggisch, P., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00006 · Cited by 71
A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
Howland, R. H. (2011) · Drug Safety · doi:10.2165/11593960-000000000-00000 · Cited by 67
Fromenty, B., Fréneaux, E., Labbe, G., Deschamps, D., Larrey, D. G., Lettéron, P., & Pessayre, D. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90580-7 · Cited by 65
Hepatocellular Jaundice as a Complication of Iproniazid Therapy
Rosenblum, L. (1960) · Archives of Internal Medicine · doi:10.1001/archinte.1960.00270160081010 · Cited by 65
Sertraline versus imipramine to prevent relapse in chronic depression
Koran, L. M., Gelenberg, A. J., Kornstein, S. G., Howland, R. H., Friedman, R. A., DeBattista, C., Klein, D. N., Kocsis, J. H., Schatzberg, A. F., Thase, M. E., et al. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00272-x · Cited by 64
Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism
Seree, E., Pisano, P., Placidi, M., Rahmani, R., & Barra, Y. (1993) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.1993.tb00219.x · Cited by 59
Trazodone-Induced Hepatotoxicity: A Case Report With Comments on Drug-Induced Hepatotoxicity
Fernandes, N. F., Martin, R. R., & Schenker, S. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.t01-1-01780.x · Cited by 58
The hepatic safety profile of duloxetine: a review
McIntyre, R. S., Panjwani, Z. D., Nguyen, H. T., Woldeyohannes, H. O., Alsuwaidan, M. T., Soczynska, J. K., Lourenço, M. T. C., Konarski, J. Z., & Kennedy, S. H. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.3.281 · Cited by 56
Inhibition of Trazodone Metabolism by Thioridazine in Humans
Yasui, N., Otani, K., Kaneko, S., Ohkubo, T., Osanai, T., Ishida, M., Mihara, K., Kondo, T., Sugawara, K., & Fukushima, Y. (1995) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199508000-00003 · Cited by 55
Acute Hepatitis Due to Fluoxetine Therapy
Cai, Q., Benson, M. A., Talbot, T. J., Devadas, G., Swanson, H. J., Olson, J. L., & Kirchner, J. P. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.7.692 · Cited by 55
Prolonged cholestasis and progressive hepatic fibrosis following imipramine therapy
Horst, D. A., Grace, N. D., & LeCompte, P. M. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90383-2 · Cited by 52
Drug points: Paroxetine and hepatotoxicity
Benbow, S. J., & Gill, G. (1997) · BMJ · doi:10.1136/bmj.314.7091.1387a · Cited by 51
Pyykkönen, A.-J., Räikkönen, K., Tuomilehto, J., Eriksson, J. G., Groop, L., & Isomaa, B. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.543921 · Cited by 48
Choy, E. H. S., Mease, P. J., Kajdasz, D. K., Wohlreich, M. M., Crits-Christoph, P., Walker, D. J., & Chappell, A. S. (2009) · Clinical Rheumatology · doi:10.1007/s10067-009-1203-2 · Cited by 47
Case Report: Fulminant Hepatic Failure Involving Duloxetine Hydrochloride
Hanje, A. J., Pell, L. J., Votolato, N. A., Frankel, W. L., & Kirkpatrick, R. B. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.04.018 · Cited by 44
Lethal Hepatic Necrosis After Therapy With Imipramine and Desipramine
Powell, W. J. (1968) · JAMA · doi:10.1001/jama.1968.03150030098027 · Cited by 43
Venlaxafine-Associated Hepatitis
Horsmans, Y., Clercq, M. D., & Sempoux, C. L. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-11-199906010-00014 · Cited by 42
Chronic hepatitis related to use of fluoxetine.
Johnston, D. E., & Wheeler, D. E. (1997) · PubMed · Cited by 41
Persky, S. E., & Reinus, J. F. (2003) · Digestive Diseases and Sciences · doi:10.1023/a:1023007831047 · Cited by 41
Acute Hepatic Necrosis Following Treatment with Amitriptyline and Diazepam
Cunningham, M. L. (1965) · The British Journal of Psychiatry · doi:10.1192/bjp.111.480.1107 · Cited by 39
Case Report: Acute Liver Failure After Treatment with Nefazodone
Lucena, M. I., Andrade, R. J., Gómez‐Outes, A., Rubio, M., & Cabello, M. R. (1999) · Digestive Diseases and Sciences · doi:10.1023/a:1026620029470 · Cited by 38
Mirtazapine-Induced Hepatotoxicity
Hui, C., Yuen, M., Wong, W., et al. (2002) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200209000-00014 · Cited by 38
A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression
Amerongen, A. P. V., Ferrey, G., & Tournoux, A. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00422-0 · Cited by 38
Paroxetine Associated Hepatotoxicity: A Report of 3 Cases and a Review of the Literature
Azaz‐Livshits, T., Hershko, A. Y., & Ben‐Chetrit, E. (2002) · Pharmacopsychiatry · doi:10.1055/s-2002-31515 · Cited by 38
Fulminant Chemical Hepatitis Possibly Associated with Donepezil and Sertraline Therapy
Verrico, M. M., Nace, D. A., & Towers, A. L. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb03879.x · Cited by 38
Drug-induced rash with eosinophilia and systemic symptoms syndrome with bupropion administration
Bagshaw, S. M., Cload, B. W. A., Gilmour, J. G., Leung, S. T., & Bowen, T. J. (2003) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)61853-4 · Cited by 36
Venlafaxine-Associated Hepatitis
Cardona, X., Ávila, A., & Castellanos, P. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-5-200003070-00016 · Cited by 36
Nankivell, B. J., Bhandari, P., & Koller, L. J. (1994) · BMJ · doi:10.1136/bmj.309.6951.378 · Cited by 35
CHU, A. G., GUNSOLLY, B. L., SUMMERS, R. W., ALEXANDER, B., MCCHESNEY, C., & TANNA, V. L. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-99-1-128_3 · Cited by 35
Symptomatic liver injury probably related to sertraline.
Hautekèete, M., Colle, I. O., Vlierberghe, H. V., & Elewaut, A. (1998) · PubMed · Cited by 34
Gahr, M. L., Freudenmann, R. W., Connemann, B. J., Hiemke, C., & Schönfeldt‐Lecuona, C. (2013) · Pharmacopsychiatry · doi:10.1055/s-0033-1353156 · Cited by 34
Hepatitis Caused by Amitriptyline Therapy
YON, J. L. (1975) · JAMA · doi:10.1001/jama.1975.03250080035013 · Cited by 34
Bricquir, Y. L., Larrey, D. G., Blanc, P., Pageaux, G., & Michel, H. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(94)80237-8 · Cited by 34
Cross hepatotoxicity between tricyclic antidepressants.
Larrey, D. G., RUEFF, B., Pessayre, D., Danan, G., Algard, M., Genève, J., & Benhamou, J. P. (1986) · Gut · doi:10.1136/gut.27.6.726 · Cited by 34
Sertraline hepatotoxicity: Report of a case and review of the literature
Collados, V., Hallal, H., & Andrade, R. J. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1192-7 · Cited by 33
Acute fatal hepatitis related to sertraline
Fartoux-Heymann, L., Hézode, C., Zafrani, E. S., Dhumeaux, D., & Mallat, A. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00159-3 · Cited by 32
CASE REPORT: Acute Hepatitis Induced by Bupropion
Hu, K., Tiyyagura, L., Kanel, G. C., & Redeker, A. G. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005553405313 · Cited by 32
Trazodone-induced hepatotoxicity and leukonychia
Longstreth, G. F., & Hershman, J. (1985) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(85)80328-5 · Cited by 31
Hepatitis secondary to fluoxetine treatment
Friedenberg, F. K., & Rothstein, K. D. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.580a · Cited by 30
Sertraline Hepatotoxicity: Report of a Case and Review of the Literature
Tabak, F., Gündüz, F., Tahan, V., Tabak, Ö., & Özaras, R. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0524-3 · Cited by 30
Case Report: Reversible Nefazodone-Induced Liver Failure
Eloubeidi, M. A., Gaede, J. T., & Swaim, M. W. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005558015787 · Cited by 29
A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report
Humayun, F., Shehab, T. M., Tworek, J. A., & Fontana, R. J. (2007) · Journal of Medical Case Reports · doi:10.1186/1752-1947-1-88 · Cited by 29
Hepatitis Associated with Low-Dose Venlafaxine for Postmenopausal Vasomotor Symptoms
Phillips, B. B., Digmann, R. R., & Beck, M. G. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g339 · Cited by 28
Alvaro, D., Muda, A. O., Moscatelli, R., & Attili, A. F. (2001) · Digestive and Liver Disease · doi:10.1016/s1590-8658(01)80049-9 · Cited by 27
Hepatic Effects of Duloxetine-II: Spontaneous Reports and Epidemiology of Hepatic Events
Wernicke, J., Acharya, N. V., Strombom, I., Gahimer, J., D’Souza, D. N., DiPietro, N. A., & Uetrecht, J. (2008) · Current Drug Safety · doi:10.2174/157488608784529198 · Cited by 27
Fulminant Hepatic Failure Induced by Venlafaxine and Trazodone Therapy: A Case Report
Detry, O., Delwaide, J., Roover, A. D., Hans, M.-F., Delbouille, M., Monard, J., & Honoré, P. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2009.09.022 · Cited by 27
Hepatic injury caused by mianserin.
Otani, K., Kaneko, S., Tasaki, H., & Fukushima, Y. (1989) · BMJ · doi:10.1136/bmj.299.6697.519-a · Cited by 26
Severe hepatotoxicity with jaundice associated with paroxetine
Odeh, M., Misselevech, I., Boss, J. H., & Oliven, A. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.04060.x · Cited by 26
Chronic Active Hepatitis Associated with Trazodone Therapy
Beck, P. L., Bridges, R. J., Demetrick, D. J., Kelly, J. K., & Lee, S. S. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-10-199305150-00006 · Cited by 26
Agomelatine-induced hepatotoxicity
Štuhec, M. (2013) · Wiener klinische Wochenschrift · doi:10.1007/s00508-013-0344-0 · Cited by 26
Trazodone and Intrahepatic Cholestasis
Sheikh, K. H., & NIES, A. S. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-99-4-572_1 · Cited by 25
Severe liver injury due to phenelzine with unique hepatic deposition of extracellular material
Bonkovsky, H. L., Blanchette, P. L., & Schned, A. R. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90826-0 · Cited by 25
Jaundice Associated with Amitriptyline
Morgan, D. H. (1969) · The British Journal of Psychiatry · doi:10.1192/bjp.115.518.105 · Cited by 25
Hepatotoxicity Related to Citalopram
López-Torres, E., Lucena, M. I., Seoane, J., et al. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.5.923-a · Cited by 24
Venlafaxine-induced Cholestatic Hepatitis: Case Report and Review of Literature
Stadlmann, S., Portmann, S., Tschopp, S., & Terracciano, L. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31826af296 · Cited by 24
Cross hepatotoxicity between tricyclic antidepressants and phenothiazines.
Rémy, A.-J., Larrey, D. G., Pageaux, G., Ribstein, J., Ramos, J., & Michel, H. (1995) · PubMed · Cited by 23
Effect of hospitalisation on liver enzymes in healthy subjects
Narjes, H., & Nehmiz, G. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000142 · Cited by 23
Acute liver injury secondary to sertraline
Suen, C. L. W., Boyapati, R. K., Simpson, I. J., & Dev, A. T. (2013) · BMJ Case Reports · doi:10.1136/bcr-2013-201022 · Cited by 23
Amitriptyline-Induced Fulminant Hepatitis
Danan, G., Bernuau, J., Moullot, X., Degott, C., & Pessayre, D. (2009) · Digestion · doi:10.1159/000199103 · Cited by 23
Acute Liver Failure with Concurrent Bupropion and Carbimazole Therapy
Khoo, A.-L., Tham, L., Lee, K.-H., & Gek-Kee, L. (2003) · Annals of Pharmacotherapy · doi:10.1177/106002800303700212 · Cited by 21
CASE REPORT: Hepatotoxicity in Patients with Cirrhosis, an Often Unrecognized Problem
Andrade, R. J., Lucena, M. I., Fernández, C., Vega, J. L., & Camargo, R. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1010627518254 · Cited by 21
Phenelzine-Induced Fulminant Hepatic Failure
Gómez‐Gil, E., Salmeron, J. M., & Mas, A. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-7-199604010-00014 · Cited by 20
The Rise of Serum Aminotransferases in a Patient Treated with Bupropion
Oslin, D. W., & Duffy, K. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199310000-00015 · Cited by 20
Acute Liver Damage Possibly Related to Sertraline and Venlafaxine Ingestion
Kim, K. Y., Hwang, W. S., & Narendran, R. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18155 · Cited by 20
Hepatic Failure Associated with Imipramine Therapy
Shaefer, M. S., Edmunds, A. L., Markin, R. S., Wood, R. P., Pillen, T. J., & Shaw, B. W. (1990) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1990.tb02551.x · Cited by 19
Intrahepatic cholestasis associated with moclobemide leading to death
Timmings, P. L., & Lamont, D. L. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90114-2 · Cited by 18
Duloxetine for Depression and the Incidence of Hepatic Events in Adults
Xue, F., Strombom, I., Turnbull, B., Zhu, S., & Seeger, J. D. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822347d9 · Cited by 16
Lai, C. (2012) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.11040083 · Cited by 16
[Acute hepatitis during treatment with fluoxetine].
Mars, F., Roque, G. D. D. L., & Goissen, P. (1991) · PubMed · Cited by 15
Mirtazapine-Associated Dose-Dependent and Asymptomatic Elevation of Hepatic Enzymes
Adetunji, B., Basil, B., Mathews, M., & Osinowo, T. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h537 · Cited by 15
Duloxetine-Induced Liver Injury in Patients with Major Depressive Disorder
Kang, S., Park, Y. M., Lee, H., & Yoon, B. (2011) · Psychiatry Investigation · doi:10.4306/pi.2011.8.3.269 · Cited by 15
A Study of Blood Count and Serum Transaminase in Prolonged Treatment with Amitriptyline
Holmberg, M. B., & Jansson, B. (1962) · The Journal of New Drugs · doi:10.1177/009127006200200606 · Cited by 14
Agomelatina: fallo hepático fulminante en paciente con hígado graso
Gruz, F., Raffa, S., Santucci, C., Papale, R. M., Videla, M. G., Fernández, M. G., Yantorno, S. E., & Descalzi, V. (2013) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2013.04.008 · Cited by 13
Concurrent Agranulocytosis and Hepatitis Secondary to Clomipramine Therapy
Alderman, C. P., Atchison, M., & McNeece, J. I. (1993) · The British Journal of Psychiatry · doi:10.1192/bjp.162.5.688 · Cited by 13
FATAL CHOLESTATIC JAUNDICE ASSOCIATED WITH AMITRIPTYLIN
Randeva, H. S., Bangar, V., Sailesh, S., & Hillhouse, E. (2000) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2000.tb11932.x · Cited by 13
Hepatotoxicity Related to Citalopram
LOPEZ-TORRES, E. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.923-a · Cited by 12
Fatal cholestatic jaundice associated with amitriptyline.
Randeva, H., Bangar, V., Sailesh, S., & Hillhouse, E. W. (2000) · PubMed · Cited by 11
Case Report of Hepatotoxicity Associated with Maprotiline
Weinstein, R. P., & Gosselin, J. Y. (1988) · The Canadian Journal of Psychiatry · doi:10.1177/070674378803300314 · Cited by 11
Drug-Induced Liver Disease Related to Citalopram
Neumann, H., Csepregi, A., Evert, M., & Malfertheiner, P. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318167b8e1 · Cited by 10
[Acute hepatitis during treatment with fluoxetine].
Bobichon, R., Bernard, G., & Mion, F. (1993) · PubMed · Cited by 10
Hepatotoxicidad asociada a sertralina
Collados Arroyo, V., Plaza Aniorte, J., Hallal, H., & Pérez-Cuadrado, E. (2008) · Farmacia Hospitalaria · doi:10.1016/s1130-6343(08)72814-9 · Cited by 9
Hepatitis Caused by Antidepressive Therapy with Maprotiline and Opipramol
Braun, J. M., Geiger, R., Wehner, H., Schäffer, S., & Berger, T. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979319 · Cited by 9
Hepatic Failure Associated with Imipramine Therapy
Ilan, Y., Samuel, D., REYNES, M., & Tur‐Kaspa, R. (1996) · Pharmacopsychiatry · doi:10.1055/s-2007-979549 · Cited by 9
Cholestatic Jaundice Induced by Duloxetine in a Patient with Major Depressive Disorder
Park, Y. M., Lee, B.-H., Lee, H., & Kang, S. (2010) · Psychiatry Investigation · doi:10.4306/pi.2010.7.3.228 · Cited by 9
Lefebure, B., Castot, A., Danan, G., Elmalem, J., Jean-Pastor, M.-J., & Ml, E. (1984) · PubMed · Cited by 9
[Hepatotoxicity of mianserin: a case with positive reintroduction].
Jc, B., Biour, M., Cadot, T., & Jp, L. (1992) · PubMed · Cited by 9
Mirtazapine-Induced Hepatocellular-Type Liver Injury
Kang, S., Yoon, B.-M., & Park, Y. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q078 · Cited by 7
Hepatotoxicity associated with maprotiline therapy: case report.
Moldawsky, R. J. (1984) · PubMed · Cited by 7
Acute Liver Failure with Concurrent Bupropion and Carbimazole Therapy
Khoo, A.-L., Tham, L., Lee, K.-H., & Gek-Kee, L. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c159 · Cited by 7
Hepatotoxicity Following Treatment with Maprotiline
Aleem, A., & Lingam, V. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198702000-00028 · Cited by 6
[Acute mixed hepatitis caused by tianeptine].
Balleyguier, C., Stérin, D., Ziol, M., & Jc, T. (1996) · PubMed · Cited by 6
Hepatitis tóxica por escitalopram
Antoñana, A. D. V., Polo, I. O., Sastre, E. R., & Osset, E. M. (2008) · Medicina Clínica · doi:10.1016/s0025-7753(08)75510-6 · Cited by 4
[Acute benign hepatitis probably due to maprotiline].
Prudent, A., Marchetti, B., Pignol, D., Lacroix, G., Bouckson, G., & Legré, M. (1988) · PubMed · Cited by 3
Maille, F., Duvoux, C., Cherqui, D., Radier, C., Zafrani, É. S., & Dhumeaux, D. (1999) · PubMed · Cited by 3
Hepatotoxicidad por citalopram
Merino, M. I. R., Carrero, A. A., García, J. F. Á., & Martínez, J. A. (2010) · Medicina Clínica · doi:10.1016/j.medcli.2010.01.009 · Cited by 1
Cited by
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
“The antidepressants with the highest risk of hepatotoxicity include iproniazid, nefazodone, phenelzine, venlafaxine, imipramine, amitriptyline, duloxetine, bupropion, trazodone, tianeptine and agomelatine (160-162).”
BackgroundCarvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
Wang, S.-M., Han, C., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Chonnam Medical Journal · doi:10.4068/cmj.2018.54.2.101 · Cited by 299
“More importantly, experts believe that it is impossible to prevent idiopathic drug induced liver injury, but the severity of the reaction may be minimized with prompt recognition and early withdrawal of the agent.(46,47) A quantitative signal detection analysis using pharmacovigilance data from the Uppsala Monitoring…”
MethodResultBrown, A. C. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2016.07.001 · Cited by 77
Metadata
- Authors
- Voican, C. S., Corruble, E., Naveau, S., & Perlemuter, G.
- Venue
- American Journal of Psychiatry
- Published
- 2014-04
- Volume
- 171
- Issue
- 4
- Pages
- 404-415
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2113278271
- Cited by
- 275
- References
- 143
- FWCI
- 19.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.